1. A lubricating composition comprising a base oil, an aralkylated diphenylamine, and a phenol compound having a molecular weight of not less than 340.
2. A lubricating composition as recited in claim 1, wherein the phenol compound has a molecular weight not less than 340 but not greater than 1,500.
3. A lubricating composition as recited in claim 1 or 2, wherein the base oil has a flash point of not lower than 180\xb0 C. and wherein the lubricating composition is a grease composition which additionally comprises a thickening agent.
4. A lubricating composition as recited in claim 3, which contains 0.01 to 10% by mass of the aralkylated diphenylamine, 0.01 to 10% by mass of the phenol compound having a molecular weight of not less than 340 and 10 to 30% by mass of the thickening agent, based on the grease composition.
5. A lubricating composition as recited in claim 1 or 2, which is a lubricating oil composition and contains 0.01 to 10% by mass of the aralkylated diphenylamine and 0.01 to 10% by mass of the phenol compound having a molecular weight of not less than 340, based on the lubricating oil composition.
6. A lubricating composition as recited in any one of claims 1 to 5, wherein the aralkylated diphenylamine is represented by the following chemical formula (1):
wherein R1 and R4 each independently represent a C0 to C24 alkyl group and R2 and R3 each independently represent a C1 to C5 alkylene group.
7. A lubricating composition as recited in any one of claims 1 to 6, wherein the phenol compound having a molecular weight of not less than 340 is represented by the following chemical formula (2):
wherein R5 represents a C1 to C18 alkyl group, R6 represents a C1 to C5 alkylene group, R7 represents a C1 to C24 alkyl group and n is 1 or 2.
8. A lubricating composition as recited in any one of claims 1 to 6, wherein the phenol compound having a molecular weight of not less than 340 is a bisphenol compound.
9. A lubricating composition as recited in claim 3, 4, 6, 7 or 8, wherein the thickening agent is a complex soap or a urea compound.
10. A lubricating composition as recited in any one of claims 3 to 8, wherein the base oil has a flash point of not less than 200\xb0 C.
11. A lubricating composition as recited in claim 1, 2, 3, 4, 6, 7, 8 or 9, which has a dropping point of not less than 230\xb0 C.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. An attenuated non-segmented negative-sense RNA virus comprising at least one mutation in the L gene wherein the mutation reduces viral replication.
2. The virus of claim 1 wherein the at least one mutation results in an amino acid modification in Domain VI of the L protein.
3. The virus of claim 1 wherein the at least one mutation results in a modification to an amino acid residue conserved among at least three non-segmented negative-sense RNA viruses.
4. The virus of claim 1 wherein at least one mutation results in a modification to an amino acid residue conserved among at least five non-segmented negative-sense RNA viruses.
5. The virus of claim 1 wherein the at least one mutation results in a modification to the L protein of vesicular stomatitis virus at an amino acid position selected from the group consisting of K1651, G1670, D1671, G1672, S1673, G1675, D1735, D1762, K1795, and E1833 or an amino acid adjacent or proximal thereto.
6. The virus of claim 5 wherein the amino acid position is selected from the group consisting of K1651, G1670, G1672, G1675, D1735, K1795, and E1833 or a combination thereof.
7. The virus of claim 5 wherein at least one mutation results in an amino acid substitution.
8. The virus of claim 5 wherein the virus comprises at least two mutations.
9. The virus of claim 5 wherein the virus comprises at least three mutations.
10. The virus of claim 5 wherein the virus comprises at least four mutations.
11. The virus of claim 1 wherein the at least one mutation alters an amino acid located at the L protein surface as predicted by protein modeling or crystallography.
12. (canceled)
13. The virus of claim 5 wherein at least one mutation alters an amino acid adjacent to K1651, G1670, G1675, D1735, D1762, K1795, and E1833.
14. The virus of claim 5 wherein the mutation results in a deletion of one or more amino acids.
15. The virus of claim 5 wherein the mutation results in an insertion of one or more amino acids.
16. The virus of claim 1 wherein mRNA cap methylation activity is reduced.
17. The virus of claim 1 wherein mRNA cap methylation activity is reduced by at least 50%.
18. The virus of claim 1 wherein the virus substantially retains its ability to express N, P, M or G protein.
19. The virus of claim 31 wherein the virus is selected from the group consisting of: Avulavirus; Newcastle disease virus; Henipavirus; Hendravirus; Nipah virus; Morbillivirus; measles; rinderpest; canine distemper; Respiro virus; Sendai; human parainfluenza viruses 1 and 3; bovine parainfluenza virus; Rubulavirus; mumps; simian parainfluenza virus 5; human parainfluenza virus 2; menangle virus; Pneumoviridae; human respiratory syncytial virus; pneumoniavirus; respiratory syncytial virus; Metapneumo virus; pneumovirus; metapneumo virus; Cytorhabdo virus; Lettuce necrotic yellows virus; Ephemerovirus; ephemeral fever virus; Lyssavirus; rabies; mokola; lyssavirus; Novirhabdovirus; infectious hematopoietic necrosis virus; viral hemorrhagic septicemia; Nucleorhabdo virus; sonchus yellow net virus; potato yellow dwarf virus; Vesiculovirus; Vesicular stomatitis Indiana virus; Vesicular stomatitis New Jersey virus; spring viremia; Marburg virus; and Ebola virus.
20. The virus of claim 1 further comprising a heterologous polynucleotide.
21. The virus according to claim 20 wherein the heterologous polynucleotide encodes an antigen.
22. A pharmaceutical composition comprising the virus of claim 1 and a pharmaceutically acceptable carrier.
23. A method of vaccinating an animal comprising administering the pharmaceutical composition of claim 22.
24. A method of treating a tumor comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 22.
25. A method of delivering a polynucleotide to an animal or plant comprising administering the virus of claim 20.
26. (canceled)
27. (canceled)
28. The virus of claim 20 wherein the heterologous polynucleotide is RNA, siRNA or microRNA.
29. The method of claim 23 wherein the subject is a human.
30. The virus of claim 1 wherein the virus is of the order of Mononegavirales.
31. The virus of claim 30 wherein the virus is of a family selected from the group consisting of Rhabdoviridae, Filoviridae and Paramyxoviridae.
32. The virus of claim 11, wherein the at least one mutation occurs at the surface of the vesicular stomatitis virus L protein at an amino acid position selected from the group consisting of: K1651, D1762, K1795 and E1833.